TY - JOUR
T1 - Evaluation of peripheral blood mononuclear cell collection by leukapheresis
AU - Chen, Jian
AU - Goss, Cheryl
AU - Avecilla, Scott T.
AU - Hong, Hong
AU - Walsh, Eileen
AU - Wuest, David
AU - Maslak, Peter
AU - Pessin, Melissa S.
N1 - Funding Information:
From the Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Address reprint requests to: Jian Chen, MD, PhD, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 327 East 64th Street, New York, NY 10065; e-mail: chenj6@mskcc.org This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. Received for publication September 11, 2018; revision received December 28, 2018, and accepted December 31, 2018. doi:10.1111/trf.15186 © 2019 AABB TRANSFUSION 2019;59;1765–1772
Publisher Copyright:
© 2019 AABB
PY - 2019/5
Y1 - 2019/5
N2 - BACKGROUND: Adoptive immunotherapy using engineered lymphocytes has shown promising results in treating cancers even in patients who have failed other treatments. As the first essential step, the number of peripheral mononuclear cell (MNC) collection procedures is rapidly increasing. In this retrospective study, we reviewed the collection results to determine factors that affect MNC collection. STUDY DESIGN AND METHODS: We reviewed 184 collections that were performed on 169 adult allogenic donors and patients with acute lymphoid leukemia, chronic lymphoid leukemia, lymphoma, multiple myeloma, or solid-organ tumors. All the leukapheresis procedures were performed after a complete cell count with differential was obtained. Total blood volume (TBV) was defined as processed blood volume divided by patient blood volume. RESULTS: There was a significant association between the precollection MNC count (pre-MNC) and the MNC yields normalized by TBV (r = 0.926; p < 0.001) and a regression formula was created to predict MNC yields. Multiple regression analyses showed that pre-MNC, TBV, and precollection hemoglobin were strongly associated with MNC yield (R 2 = 0.866; F (3180) = 388.472; p < 0.001), and pre-MNC had the greatest influence on MNC yield (β = 0.960; p < 0.001) followed by TBV (β = 0.302; p < 0.001), and Hgb (β = 0.136; p < 0.001). CONCLUSION: Our results suggest that the optimal time for MNC collection can be determined based on pre-MNC and that processing volume should be determined based on collection goal and pre-MNC to optimize and personalize the harvesting procedure.
AB - BACKGROUND: Adoptive immunotherapy using engineered lymphocytes has shown promising results in treating cancers even in patients who have failed other treatments. As the first essential step, the number of peripheral mononuclear cell (MNC) collection procedures is rapidly increasing. In this retrospective study, we reviewed the collection results to determine factors that affect MNC collection. STUDY DESIGN AND METHODS: We reviewed 184 collections that were performed on 169 adult allogenic donors and patients with acute lymphoid leukemia, chronic lymphoid leukemia, lymphoma, multiple myeloma, or solid-organ tumors. All the leukapheresis procedures were performed after a complete cell count with differential was obtained. Total blood volume (TBV) was defined as processed blood volume divided by patient blood volume. RESULTS: There was a significant association between the precollection MNC count (pre-MNC) and the MNC yields normalized by TBV (r = 0.926; p < 0.001) and a regression formula was created to predict MNC yields. Multiple regression analyses showed that pre-MNC, TBV, and precollection hemoglobin were strongly associated with MNC yield (R 2 = 0.866; F (3180) = 388.472; p < 0.001), and pre-MNC had the greatest influence on MNC yield (β = 0.960; p < 0.001) followed by TBV (β = 0.302; p < 0.001), and Hgb (β = 0.136; p < 0.001). CONCLUSION: Our results suggest that the optimal time for MNC collection can be determined based on pre-MNC and that processing volume should be determined based on collection goal and pre-MNC to optimize and personalize the harvesting procedure.
UR - http://www.scopus.com/inward/record.url?scp=85061425622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061425622&partnerID=8YFLogxK
U2 - 10.1111/trf.15186
DO - 10.1111/trf.15186
M3 - Review article
C2 - 30747437
AN - SCOPUS:85061425622
SN - 0041-1132
VL - 59
SP - 1765
EP - 1772
JO - Transfusion
JF - Transfusion
IS - 5
ER -